Tocilizumab controls bone turnover in early polymyalgia rheumatica - 29/04/21
, Florent Garrigues c, Eleonore Bettacchioli d, Damien Loeuille e, f, Alain Saraux a, Divi Cornec a, b, Valérie Devauchelle-Pensec a, b, 1, Yves Renaudineau d, 1Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 5 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Bone turnover is impaired in polymyalgia rheumatica with an increased resorption. |
• | Tocilizumab restores bone turnover in polymyalgia rheumatica. |
• | Increase of bone formation in associated with IL-6 level in the serum. |
• | Scanographic bone attenuation coefficient is used for the first time to evaluate bone mineral density in polymyalgia rheumatica. |
Abstract |
Objectives |
This study explores changes in the bone homeostasis by testing the N-terminal collagen type I extension propeptide (PINP) marker for osteo-formation and the carboxy-terminal region of collagen type I (CTX-I) marker for osteo-resorption in patients taking tocilizumab for polymyalgia rheumatica (PMR).
Methods |
Twenty patients were included in the prospective open-label TENOR study (Clinicaltrials.gov NCT01713842) and received three monthly tocilizumab infusions, followed by corticosteroids starting at week (W) 12. PINP and CTX-I were tested at inclusion (W0), after tocilizumab but before steroid initiation (W12), at the end of the protocol (W24) and were compared to healthy controls. Information regarding disease activity, bone mineral density using scanographic bone attenuation correlation (SBAC), inflammatory parameters and interleukin (IL)-6 levels were collected during the follow-up of the patients.
Results |
PMR patients were characterised by a reduction in bone mineral density and a higher level of CTX-I relative to healthy controls matched in age and sex at baseline. PINP levels increased at W12 (P< 0.001, versus W0) following tocilizumab introduction and CTX-I levels decreased at W24 and after steroid initiation (P=0.001, versus W0). Such modifications explain the altered correlation observed between PINP and CTX-I at W0 (r=0.255 at W0 versus r=0.641 in healthy controls) and its correction after treatment (r=0.760 at W12 and r=0.767 at W24). Finally, greater changes in PINP were observed in patients whose circulating IL-6 levels decreased after tocilizumab therapy.
Conclusions |
Control of bone turnover, in part through the inhibition of the IL-6 axis, is observed during tocilizumab and subsequent steroid treatment of PMR.
Le texte complet de cet article est disponible en PDF.Keywords : Polymyalgia rheumatica, Tocilizumab, PINP, CTX-I, IL-6, Scanographic bone attenuation coefficient
Abbreviations : CRP, CTX-I, ECR, HU, IL, PINP, PMR, PMR-AS, RA, RANK-L, SBAC, SEM, W
Plan
Vol 88 - N° 3
Article 105117- mai 2021 Retour au numéro
Article précédent
- Uveitis as the first symptom in spondyloarthritis and its association with the evolution of the disease. Results from the REGISPONSER registry
- Ignacio Gómez-García, María Lourdes Ladehesa-Pineda, María Ángeles Puche-Larrubia, Rafaela Ortega-Castro, Pilar Font-Ugalde, Verónica Pérez-Guijo, Alejandro Escudero-Contreras, Gonzalo Diaz-Villalón, Clementina López-Medina, Eduardo Collantes-Estévez
- Patients and spouses coping with inflammatory arthritis: Impact of communication and spousal perceived social support and burden
- Anne-Christine Rat, Morgane Brignon, Catherine Beauvais, Martine Beranger, Emilie Boujut, Jean-David Cohen, Caroline Delannoy, Isabelle Griffoul-Espitalier, Joelle Kivits, Didier Poivret, Corinne Thevenot, Sonia Trope, Aurélie Untas, Christel Vioulac, Camille Alleyrat, Janine-Sophie Giraudet-Le Quintrec, proxyRIC working group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?